Taking cellular immunotherapy to the next level

We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).

Find out more

oNKord®  

Our lead investigational product

oNKord® is an off-the-shelf, Natural Killer (NK) cellular immunotherapy product. Based on umbilical cord blood (UCB) derived CD34+ stem cells, oNKord® has many advantages, such as off-the-shelf, readily available with minimum waiting time; safe, since oNKord® does not cause Cytokine Release Syndrome (CRS) and cost-effective.

Find out more

Glycostem Pipeline

Glycostem is developing a pipeline of cellular immunotherapy therapies, which has the potential to redefine standards of care across various type of cancer. Besides of oNKord® as our lead investigational product, we are developing viveNKTM, Chimeric Antigen Receptor (CAR)-engineered NK cell therapy and also T-cell receptor expression NK cell products as well as NK-cell antibody/engager ADCC. Our vision is to be the leading innovative NK cell therapy company covering strong unmet medical needs.

Find out more

oNKord® phase I/IIa pivotal trial

 

Glycostem initiated phase I/IIa pivotal trial to evaluate the safety and efficacy of oNKord® in patients with Acute Myeloid Leukemia (AML) in November 2020. The WiNK trial will enrol 33 AML patients in total, in 5 European countries. The recruitment of patients for the WiNK trial is open.

Find out more
blue_cell

Pioneering, developing and manufacturing

Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK-cell production processes.During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second generation product: Chimeric Antigen Receptor (CAR)-engineered NK cells. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.

Learn more

Press releases

Inaleucel Added to WHO Recommended List as INN for oNKord®

20th April 2023 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has announced that Inaleucel has been added to the WHO recommended list as the international non-proprietary name (INN) oNKord®.This

Click here to open
Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem’s lead product - oNKord®

1st Aug 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, and medac GmbH, an international pharmaceutical company based in Germany, will partner to commercialize Glycostem’s lead product, oNKord®.

Click here to open
Glycostem announces new data presentation at EHA 2022 Congress highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia

13th May 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that an abstract on further findings of patients treated in its phase I/IIa WiNK trial have been acce

Click here to open
Global popap